Table 1.
Baseline characteristics of the study subjects
|
Variable
|
Group I (n = 55)
|
Group II (n = 55)
|
P
value
|
| Age (yr) | 57.58 ± 7.75 | 56.29 ± 7.69 | 0.38 |
| BMI (kg/m²) | 25.41 ± 3.05 | 24.81 ± 3.79 | 0.35 |
| WC (cm) | 83.02 ± 5.17 | 81.42 ± 6.11 | 0.14 |
| Serum CHOL (mg/dL) | 175.33 ± 40.68 | 180.12 ± 37.12 | 0.52 |
| Serum TG (mg/dL) | 175.16 ± 48.67 | 150.09 ± 42.67 | 0.05 |
| Serum HDL-C (mg/dL) | 38.57 ± 6.89 | 40.59 ± 8.17 | 0.16 |
| Serum LDL-C (mg/dL) | 123.68 ± 27.73 | 113.17 ± 31.58 | 0.06 |
| FBS (mg/dL) | 92.89 ± 8.81 | 95.71 ± 10.14 | 0.12 |
| PPBS (mg/dL) | 133.33 ± 5.53 | 133.15 ± 3.76 | 0.84 |
| HbA1c (%) | 5.24 ± 0.19 | 5.28 ± 0.14 | 0.14 |
| Serum creatinine (mg/dL) | 0.79 ± 0.16 | 0.85 ± 0.23 | 0.09 |
| Serum hsCRP (μg/mL) | 5.26 ± 1.94 | 1.41 ± 0.44 | 0.00b |
| Plasma HC (μmol/L) | 18.13 ± 5.39 | 12.83 ± 3.99 | 0.00b |
| Lp(a) (μg/mL) | 294.36 ± 202.22 | 251.22 ± 221.42 | 0.28 |
| sRAGE (pg/mL) | 285 (30-2490) | 540 (90-3450) | 0.02a |
| Category 1 (< 225) | 24 | 4 | 0.00b |
| Category 2 (≥ 225-< 397.5) | 8 | 19 | 0.01a |
| Category 3 (≥ 397.5-< 730) | 13 | 15 | 0.66 |
| Category 4 (≥ 730) | 10 | 17 | 0.12 |
| Hypertension | 30 | 24 | 0.25 |
| Family history | 26 | 14 | 0.01a |
a
P < 0.05.
b
P < 0.01.
Data are means ± SD, median (interquartile range), or frequency counts, as appropriate. BMI: Body Mass Index; CHOL: Cholesterol; FBS: Fasting blood sugar; HbA1c: Glycosylated hemoglobin; HC: Homocysteine; HDL-C: High-density lipoprotein cholesterol; hsCRP: High-sensitivity C-reactive protein; LDL-C: Low-density lipoprotein cholesterol; Lp(a): Lipoprotein (a); PPBS: Post prandial blood sugar; sRAGE: Soluble receptor for advanced glycation end products; TG: Triglycerides; WC: Waist circumference.